Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2.
10.3760/cma.j.issn.0253-2727.2023.10.008
- VernacularTitle:BCMA-CAR-T细胞治疗难治复发性多发性骨髓瘤患者血清脂质水平和营养状态变化及其影响：基于LEGEND-2的回顾性研究
- Author:
Xue Zhu XU
1
;
Rui LIU
1
;
Wan Hong ZHAO
1
;
Yun YANG
1
;
Jie LIU
1
;
Yu Gang ZHANG
1
;
Ju BAI
1
;
Ai Li HE
1
Author Information
1. Department of Hematopathology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
- Publication Type:Journal Article
- Keywords:
CONUT score;
Chimeric antigen receptor T cell;
Multiple myeloma;
Nutritional status;
Prognostic factors;
Serum lipid level
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Nutritional Status;
Retrospective Studies;
Receptors, Chimeric Antigen/therapeutic use*;
B-Cell Maturation Antigen/therapeutic use*;
Cell- and Tissue-Based Therapy;
Lipids/therapeutic use*
- From:
Chinese Journal of Hematology
2023;44(10):838-844
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2. Methods: The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis. Results: Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal on average. At 8-14 d after CAR-T-cell infusion, serum albumin (ALB), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and apolipoprotein A1 (Apo A1) levels dropped to the minimum, whereas CONUT scores reached the maximum. In addition to TG, apolipoprotein B (Apo B) levels increased compared with baseline. After CAR-T-cell therapy, the patients' serum lipid levels significantly increased with well-improved nutritional status. Spearman's related analysis showed that TC, HDL, and ApoA1 levels after CAR-T-cell injection were significantly negatively correlated with the grade of cytokine-release syndrome (CRS) (r=-0.548, P=0.003; r=-0.444, P=0.020; r=-0.589, P=0.001). Furthermore, survival analysis indicated that the CONUT score was unrelated to PFS, and the median OS of patients with R/R MM in the high-CONUT score group was shorter than that in the low-CONUT score group (P=0.046) . Conclusions: During CAR-T-cell therapy, hypolipidemia and poor nutritional status were aggravated, which is possibly related to CRS. The patients' serum lipid levels and nutritional status were significantly improved after CAR-T-cell treatment. The CONUT score affected the median OS in patients treated with CAR-T-cells. Therefore, specific screening and intervention for nutritional status in patients receiving CAR-T-cell therapy are required.
